Press Releases :: Sonnet BioTherapeutics, Inc. (PURR)

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

Nov 30, 2020 8:30am EST

Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010

Sep 01, 2020 8:30am EDT

Sonnet Announces New Preclinical Data for SON-1010 (Interleukin 12-F(H)AB)

Aug 25, 2020 7:30am EDT

Sonnet BioTherapeutics Receives $10.5 Million from Exercise of Series A Warrants

Aug 14, 2020 7:30am EDT

Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update

Aug 04, 2020 7:35am EDT

Sonnet BioTherapeutics Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million

Aug 04, 2020 7:30am EDT

Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics

Jul 20, 2020 7:30am EDT

Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12

Jul 15, 2020 7:30am EDT

Sonnet BioTherapeutics to Present at the 2020 BTIG Virtual Biotechnology Conference

May 18, 2020 7:30am EDT

Sonnet BioTherapeutics Holdings Provides Business and Earnings Update

Apr 06, 2020 7:30am EDT

Sonnet BioTherapeutics Announces Formation of Scientific Advisory Board

1...
4
5
6
7
8
9
10
11
12
13